| Ident. | Authors (with country if any) | Title |
|---|
| 000004 |
Susan H. Fox [Canada] ; Leonard Verhagen Metman [États-Unis] ; John G. Nutt [États-Unis] ; Matthew Brodsky [États-Unis] ; Stewart A. Factor [États-Unis] ; Anthony E. Lang [Canada] ; Laura E. Pope [États-Unis] ; Nadine Knowles [États-Unis] ; João Siffert [États-Unis] | Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. |
| 000123 |
Anthony H V. Schapira [Royaume-Uni] ; Susan H. Fox [Canada] ; Robert A. Hauser ; Joseph Jankovic [États-Unis] ; Wolfgang H. Jost [Allemagne] ; Christopher Kenney [États-Unis] ; Jaime Kulisevsky [Espagne] ; Rajesh Pahwa ; Werner Poewe [Autriche] ; Ravi Anand [Suisse] | Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. |
| 000224 |
Anna Chang [Canada] ; Susan H. Fox [Canada] | Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management. |
| 000267 |
Maria Eliza Freitas [Canada] ; Susan H. Fox [Canada] | Nondopaminergic treatments for Parkinson's disease: current and future prospects. |
| 000367 |
Renato P. Munhoz [Canada] ; Marina Picillo [Canada] ; Susan H. Fox [Canada] ; Veronica Bruno [Canada] ; Michel Panisset [Canada] ; Christopher R. Honey [Canada] ; Alfonso Fasano [Canada] | Eligibility Criteria for Deep Brain Stimulation in Parkinson's Disease, Tremor, and Dystonia. |
| 000410 |
Scott A. Norris [États-Unis] ; H A Jinnah [États-Unis] ; Alberto J. Espay [États-Unis] ; Christine Klein [Allemagne] ; Norbert Brüggemann [Allemagne] ; Richard L. Barbano [États-Unis] ; Irene Andonia C. Malaty [États-Unis] ; Ramon L. Rodriguez [États-Unis] ; Marie Vidailhet [France] ; Emmanuel Roze [France] ; Stephen G. Reich [États-Unis] ; Brian D. Berman [États-Unis] ; Mark S. Ledoux [États-Unis] ; Sarah Pirio Richardson [États-Unis] ; Pinky Agarwal [États-Unis] ; Zoltan Mari [États-Unis] ; William G. Ondo [États-Unis] ; Ludy C. Shih [États-Unis] ; Susan H. Fox [Canada] ; Alfredo Berardelli [Italie] ; Claudia M. Testa [États-Unis] ; Florence Ching-Fen Cheng [Australie] ; Daniel Truong [États-Unis] ; Fatta B. Nahab [États-Unis] ; Tao Xie [États-Unis] ; Mark Hallett [États-Unis] ; Ami R. Rosen [États-Unis] ; Laura J. Wright [États-Unis] ; Joel S. Perlmutter [États-Unis] | Clinical and demographic characteristics related to onset site and spread of cervical dystonia. |
| 000427 |
Veronica A. Bruno [Canada] ; Susan H. Fox [Canada] ; Deborah Mancini [Canada] ; Janis M. Miyasaki [Canada] | Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism. |
| 000474 |
Tiago A. Mestre [Canada] ; Isabelle Beaulieu-Boire [Canada] ; Camila C. Aquino [Canada] ; Nicolas Phielipp [États-Unis] ; Yu Yan Poon [Canada] ; Jane P. Lui [Canada] ; Julie So [Canada] ; Susan H. Fox [Canada] | What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease? |
| 000522 |
Tom M. Johnston [Canada] ; Susan H. Fox | Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates. |
| 000551 |
Yilong Ma [États-Unis] ; Tom H. Johnston [Canada] ; Shichun Peng [États-Unis] ; Chuantao Zuo [République populaire de Chine] ; James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Yihui Guan [République populaire de Chine] ; David Eidelberg [États-Unis] ; Jonathan M. Brotchie [Canada] | Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. |
| 000582 |
Kaviraja Udupa [Canada] ; Susan H. Fox [Canada] | Placebo effect in Parkinson's disease: Harnessing the mind in the treatment of PD. |
| 000641 |
Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Monoamine Reuptake Inhibitors in Parkinson's Disease |
| 000701 |
Ai Huey Tan [Malaisie] ; Sanjiv Mahadeva [Malaisie] ; Connie Marras [Canada] ; Abdul Malik Thalha [Malaisie] ; Chiun Khang Kiew [Malaisie] ; Chia Ming Yeat [Malaisie] ; Sheang Wen Ng [Malaisie] ; Sheau Phing Ang [Malaisie] ; Siew Kian Chow [Malaisie] ; Mun Fai Loke [Malaisie] ; Jamunarani S. Vadivelu [Malaisie] ; Norlinah Ibrahim [Malaisie] ; Hoi Sen Yong [Malaisie] ; Chong Tin Tan [Malaisie] ; Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Shen-Yang Lim [Malaisie] | Helicobacter pylori infection is associated with worse severity of Parkinson's disease. |
| 000770 |
Cynthia L. Comella [États-Unis] ; Susan H. Fox [Canada] ; Kailash P. Bhatia [Royaume-Uni] ; Joel S. Perlmutter [États-Unis] ; Hyder A. Jinnah [États-Unis] ; Mateusz Zurowski [Canada] ; William M. Mcdonald [États-Unis] ; Laura Marsh [États-Unis] ; Ami R. Rosen [États-Unis] ; Tracy Waliczek [États-Unis] ; Laura J. Wright [États-Unis] ; Wendy R. Galpern [États-Unis] ; Glenn T. Stebbins [États-Unis] | Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology |
| 000794 |
Camila Catherine Aquino [Canada] ; Susan H. Fox | Clinical spectrum of levodopa-induced complications. |
| 000873 |
Camila C. Aquino [Canada] ; Susan H. Fox | Understanding conversion disorders: back to Freud's theory. |
| 000877 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Katie D. Lewis [Australie] ; James B. Koprich [Canada] ; M Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada] | UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. |
| 000927 |
Ai Huey Tan [Malaisie] ; Sanjiv Mahadeva [Malaisie] ; Abdul Malik Thalha [Malaisie] ; Peter R. Gibson [Australie] ; Chiun Khang Kiew [Malaisie] ; Chia Ming Yeat [Malaisie] ; Sheang Wen Ng [Malaisie] ; Sheau Phing Ang [Malaisie] ; Siew Kian Chow [Malaisie] ; Chong Tin Tan [Malaisie] ; Hoi Sen Yong [Malaisie] ; Connie Marras [Canada] ; Susan H. Fox [Canada] ; Shen-Yang Lim [Malaisie] | Small intestinal bacterial overgrowth in Parkinson's disease. |
| 000971 |
Susan H. Fox [Canada] | Pimavanserin as treatment for Parkinson's disease psychosis. |
| 000A70 |
Amaal Al Dakheel [Canada] ; Isabelle Beaulieu-Boire ; Susan H. Fox | Emerging drugs for levodopa-induced dyskinesia. |
| 000B77 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] | 'Don't delay, start today': delaying levodopa does not delay motor complications. |
| 000C31 |
Barbara Connolly [Canada] ; Susan H. Fox [Canada] | Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease |
| 000C38 |
Philippe Huot [Canada] ; Susan H. Fox | The serotonergic system in motor and non-motor manifestations of Parkinson's disease. |
| 000C43 |
Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Susan H. Fox ; Jonathan M. Brotchie | The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. |
| 000C50 |
James B. Koprich [Canada] ; Philippe Huot ; Susan H. Fox ; Keith Jarvie ; Anthony E. Lang ; Philip Seeman ; Jonathan M. Brotchie | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. |
| 000D19 |
Susan H. Fox [Canada] | Non-dopaminergic treatments for motor control in Parkinson's disease. |
| 000E81 |
Tiago A. Mestre [Canada] ; Mateusz Zurowski ; Susan H. Fox | 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders. |
| 000E88 |
Lorraine V. Kalia [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials |
| 000F09 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tessa Snoeren [Pays-Bas] ; James B. Koprich [Canada] ; Michael P. Hill [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque |
| 001036 |
Philippe Huot [Canada] ; Susan H. Fox [Canada] | The serotonergic system in motor and non-motor manifestations of Parkinson's disease |
| 001038 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 001057 |
Susan H. Fox [Canada] | Non-dopaminergic Treatments for Motor Control in Parkinson's Disease |
| 001116 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Michael N. Gandy [Australie] ; M. Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada] | The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset |
| 001191 |
Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Ahmed Aman ; Susan H. Fox ; Jonathan M. Brotchie | L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. |
| 001249 |
Barbara S. Connolly [Canada] ; Susan H. Fox | Drug treatments for the neuropsychiatric complications of Parkinson's disease. |
| 001293 |
Tom H. Johnston [Canada] ; Zak Millar ; Philippe Huot ; Keith Wagg ; Sherri Thiele ; Danielle Salomonczyk ; Christopher J. Yong-Kee ; Michael N. Gandy ; Matthew Mcildowie ; Katie D. Lewis ; Jordi Gomez-Ramirez ; Joohyung Lee ; Susan H. Fox ; Mathew Martin-Iverson ; Joanne E. Nash ; Matthew J. Piggott ; Jonathan M. Brotchie | A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. |
| 001413 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease |
| 001477 |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Qin Li [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A critique of available scales and presentation of the non‐human primate dyskinesia rating scale |
| 001574 |
Philippe Huot [Canada] ; Susan H. Fox ; Jonathan M. Brotchie | The serotonergic system in Parkinson's disease. |
| 001723 |
Philippe Huot [Canada] ; Susan H. Fox ; Adrian Newman-Tancredi ; Jonathan M. Brotchie | Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? |
| 001778 |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
| 001786 |
Klaus Seppi [Autriche, Portugal] ; Daniel Weintraub [États-Unis] ; Miguel Coelho [Portugal] ; Santiago Perez-Lloret [France] ; Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Eva-Maria Hametner [Autriche] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease |
| 001787 |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease |
| 001824 |
Arpan R. Mehta [Canada, Royaume-Uni] ; Susan H. Fox [Canada] ; Mark Tarnopolsky [Canada] ; Grace Yoon [Canada] | Mitochondrial mimicry of multiple system atrophy of the cerebellar subtype |
| 001986 |
Susan H. Fox [Canada] ; Jonathan M. Brotchie | The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. |
| 001993 |
Benedicte Ballanger [Canada] ; Antonio P. Strafella ; Thilo Van Eimeren ; Mateusz Zurowski ; Pablo M. Rusjan ; Sylvain Houle ; Susan H. Fox | Serotonin 2A receptors and visual hallucinations in Parkinson disease. |
| 001996 |
Tom H. Johnston [Canada] ; Susan H. Fox ; Matthew J. Mcildowie ; Matthew J. Piggott ; Jonathan M. Brotchie | Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. |
| 001B23 |
Pettarusp M. Wadia [Canada] ; Gamaliel Tan [Canada] ; Renato P. Munhoz [Canada] ; Susan H. Fox [Canada] ; Stephen J. Lewis [Canada] ; Anthony E. Lang [Canada] | Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation |
| 001B51 |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates |
| 001C09 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations |
| 001C36 |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease |
| 001C77 |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates |
| 001C83 |
Benedicte Ballanger [États-Unis] ; Antonio P. Strafella [États-Unis, Canada] ; Thilo Van Eimeren [États-Unis] ; Mateusz Zurowski [États-Unis] ; Pablo M. Rusjan [États-Unis] ; Sylvain Houle [États-Unis] ; Susan H. Fox [États-Unis] | Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease |
| 001C89 |
Susan H. Fox [Canada] ; Naomi Visanji [Canada] ; Gaby Reyes [Canada] ; Philippe Huot [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom Johnston [Canada] ; Jonathan M. Brotchie [Canada] | Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson's Disease |
| 001D05 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5-HT2A Receptors in the Temporal Cortex of Parkinsonian Patients with Visual Hallucinations |
| 001E03 |
Shen-Yang Lim [Canada] ; Susan H. Fox ; Anthony E. Lang | Overview of the extranigral aspects of Parkinson disease. |
| 001F59 |
Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada] | Serotonin and Parkinson's disease: On movement, mood, and madness |
| 002073 |
Shen-Yang Lim [Canada] ; Susan H. Fox [Canada] ; Anthony E. Lang [Canada] | Overview of the Extranigral Aspects of Parkinson Disease |
| 002158 |
Susan H. Fox [Canada] ; Rosalind Chuang ; Jonathan M. Brotchie | Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy. |
| 002166 |
Susan H. Fox [Canada] ; Jonathan M. Brotchie ; Anthony E. Lang | Non-dopaminergic treatments in development for Parkinson's disease. |
| 002308 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] | Levodopa‐related motor complications—Phenomenology |
| 002373 |
Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease |
| 002379 |
Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis] | Striatal histone modifications in models of levodopa-induced dyskinesia |
| 002419 |
Cindy Zadikoff [États-Unis, Canada] ; Susan H. Fox [Canada] ; David F. Tang-Wai [Canada] ; Teri Thomsen [Canada] ; Rob M. A. De Bie [Canada, Pays-Bas] ; Pettarusup Wadia [Canada] ; Janis Miyasaki [Canada] ; Sarah Duff-Canning [Canada] ; Anthony E. Lang [Canada] ; Connie Marras [Canada] | A Comparison of the Mini Mental State Exam to the Montreal Cognitive Assessment in Identifying Cognitive Deficits in Parkinson's Disease |
| 002664 |
Valerie Voon [États-Unis, Canada] ; Susan H. Fox [Canada] | Medication-related impulse control and repetitive behaviors in parkinson disease |
| 002671 |
Teri R. Thomsen [Canada] ; Wendy R. Galpem [Canada] ; Abena Asante [Canada] ; Tamara Arenovich [Canada] ; Susan H. Fox [Canada] | Ipratropium Bromide Spray as Treatment for Sialorrhea in Parkinson's Disease |
| 002679 |
Valerie Voon [États-Unis] ; Teri Thomsen [Canada] ; Janis M. Miyasaki [Canada] ; Minella De Souza [Canada] ; Ariel Shafro [Canada] ; Susan H. Fox [Canada] ; Sarah Duff-Canning [Canada] ; Anthony E. Lang [Canada] ; Mateusz Zurowski [Canada] | Factors associated with dopaminergic drug-related pathological gambling in parkinson disease |
| 002784 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure |
| 002813 |
Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 002925 |
Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease |
| 002A01 |
Tom H. Johnston [Canada] ; Susan H. Fox ; Jonathan M. Brotchie | Advances in the delivery of treatments for Parkinson's disease. |
| 002B51 |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
